West Lafayette-based Endocyte Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, has named Caryn Barnett senior director, clinical operations with global responsibility for clinical trials. She has more than 22 years of experience in the pharmaceutical industry, most recently as director of clinical operations, North America Oncology at Eli Lilly and Co. Barnett’s accomplishments include her recent leadership in executing four simultaneous global oncology registration programs, each of which were subsequently approved by the FDA.
Also, Theresa Bruce has been appointed head of European clinical operations following 25 years in the field of clinical research, with the last 20 dedicated to oncology. She brings a significant understanding of the regulatory landscape, particularly in Europe. Additionally, Bruce played a lead role in developing next generation prostate cancer therapeutics in these regions, with her involvement in the operational execution of several phase 3 prostate cancer studies including, most notably, the development of abiraterone (Zytiga) from early-stage trials through registration.